MedTrace Logo

Handling Oxygenation Targets in COVID-19

NCT04425031 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 726

Last updated 2024-07-15

No results posted yet for this study

Summary

Patients with COVID-19 and hypoxaemic respiratory failure and admitted to the intensive care unit (ICU) are treated with supplementary oxygen as a standard. However, quality of quantity evidence regarding this practise is low. The aim of the HOT-COVID trial is to evaluate the benefits and harms of two targets of partial pressure of oxygen in arterial blood (PaO2) in guiding the oxygen therapy in acutely ill adult COVID-19 patients with hypoxaemic respiratory failure at ICU admission.

Conditions

  • Hypoxemic Respiratory Failure
  • Oxygen Toxicity

Interventions

DRUG

Low oxygenation target

Oxygen administration to achieve a PaO2 of 8 kPa (60 mmHg) from ICU admission to ICU discharge

DRUG

High oxygenation target

Oxygen administration to achieve a PaO2 of 12 kPa (90 mmHg) from ICU admission to ICU discharge

Sponsors & Collaborators

  • Rigshospitalet, Denmark

    collaborator OTHER

  • Copenhagen Trial Unit, Center for Clinical Intervention Research

    collaborator OTHER

  • Aalborg University Hospital

    lead OTHER

Principal Investigators

  • Bodil Steen Rasmussen, MD, PhD · Aalborg University Hospital, Denmark

  • Bodil Steen Rasmussen, MD, PhD · Aalborg University Hospital, Denmark

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-25
Primary Completion
2023-03-08
Completion
2024-03-08

Countries

  • Denmark
  • Norway
  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04425031 on ClinicalTrials.gov